Medexus Pharmaceuticals Inc - Asset Resilience Ratio
Medexus Pharmaceuticals Inc (MDP) has an Asset Resilience Ratio of 9.66% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Medexus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Medexus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$14.97 Million | 9.66% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$14.97 Million | 9.66% |
Asset Resilience Insights
- Limited Liquidity: Medexus Pharmaceuticals Inc maintains only 9.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Medexus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Medexus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.72% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
Annual Asset Resilience Ratio for Medexus Pharmaceuticals Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Medexus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 13.95% | CA$23.97 Million | CA$171.84 Million | +10.58pp |
| 2024-03-31 | 3.37% | CA$5.25 Million | CA$155.73 Million | -4.73pp |
| 2023-03-31 | 8.10% | CA$13.07 Million | CA$161.33 Million | +0.91pp |
| 2022-03-31 | 7.20% | CA$10.02 Million | CA$139.22 Million | -5.40pp |
| 2021-03-31 | 12.59% | CA$18.70 Million | CA$148.51 Million | +8.33pp |
| 2020-03-31 | 4.26% | CA$5.23 Million | CA$122.81 Million | -22.24pp |
| 2019-03-31 | 26.50% | CA$22.72 Million | CA$85.73 Million | -12.66pp |
| 2018-03-31 | 39.16% | CA$2.81 Million | CA$7.17 Million | -2.50pp |
| 2017-03-31 | 41.66% | CA$2.41 Million | CA$5.79 Million | -- |
About Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of… Read more